Advancing Localized Prostate Cancer Treatment: Effects of Apalutamide, ADT

By Neal Shore, MD, FACS - Last Updated: June 13, 2024

Neal Shore, MD, FACS, continues his discussion on the effects of apalutamide and ADT on patients with localized prostate cancer. Dr. Shore highlights his recent research and his beliefs on what further research is needed in the field.

Find his previous comments on this topic here.

Neoadjuvant Darolutamide, Relugolix Combination Before Radical Prostatectomy for High-Risk PC

Guru P. Sonpavde, MDLocalized | February 24, 2025

Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.

Decipher Genomic Classifier of Early Prostate Cancer and Underlying Transcriptomic Profile

Daniel Keizman, MDLocalized | February 24, 2025

Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.

Investigating Inflammasome Gene Activity and Its Impact on Prostate Cancer Outcomes

Alireza Ghoreifi, MDLocalized | February 24, 2025

Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.

Risk Stratification in High-Risk Prostate Cancer: Long-Term vs Short Term ADT

Emily MenendezLocalized | February 4, 2025

Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.

PSMA PET Utility for Determining Optimal Candidates for Focal Therapy

Rafael Sanchez-Salas, MDLocalized | January 21, 2025

Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.

Advancing Localized Prostate Cancer Treatment: Effects of Apalutamide, ADT

Related Posts